Tecentriq® (atezolizumab) +Avastin®

May 19, 2026 — F. Hoffmann‑La Roche Ltd announced it will present new clinical data at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago) spanning nine approved and investigational oncology medicines across 15+ indications, with emphasis on breast cancer.

Key updates center on giredestrant, an investigational oral selective estrogen receptor degrader (SERD) for ER‑positive/HER2‑negative breast cancer (~70% of cases). Roche will present: (1) lidERA phase III subgroup results by menopausal status to assess consistency of efficacy/safety in pre‑ vs post‑menopausal early breast cancer; prior December 2025 results showed a 30% reduction in risk of invasive disease recurrence or death, and these lidERA data have been submitted to the FDA. (2) persevERA phase III primary results of giredestrant + palbociclib vs letrozole + palbociclib first line in locally advanced/metastatic disease; the study missed its primary endpoint but showed a numerical PFS improvement. (3) evERA post‑progression analyses of giredestrant + everolimus after CDK4/6 inhibitors; FDA has accepted the NDA based on positive evERA data.

Additional ASCO highlights include early phase Ic data for brain‑penetrant HER2 TKI ZN‑A‑1041 combinations in HER2+ metastatic breast cancer, divarasib (KRAS G12C) + pembrolizumab in NSCLC (Krascendo‑170), and updated phase III SUNMO data for Lunsumio + Polivy in relapsed/refractory DLBCL. Clinical significance: supports potential new endocrine standards and chemotherapy‑free regimens; business significance includes active regulatory submissions for giredestrant.